Kodak Film Revenue Up 43% — What It Means for ECN-2 Film Labs
Kodak's second-quarter 2026 results, published August 4, show a company that no longer looks like a going-concern risk. Consolidated revenue reached $311 million, up from $263 million a year earlier, and the "film and chemicals" product line inside Kodak's Advanced Materials and Chemicals segment grew from $68 million to $97 million in the quarter alone — a jump of roughly 43%, and effectively all of the company's growth. For any lab, rental house, or film school running an ECN-2 line, this is not background financial trivia. It is the clearest signal yet that motion picture film volume is going up, film stock composition is changing, and processing capacity is the next bottleneck. Here is what the numbers mean and how to make sure your lab's ECN-2 processing setup — ECN-PRO for remjet stocks, ECN-PRO3 for AHU/remjet-free stocks — is ready for it.
Why Kodak's Q2 2026 Results Matter to Every Film Lab
Kodak's headline numbers tell a recovery story: gross profit rose from $51 million to $82 million, lifting gross margin from 19% to 26%, while Operational EBITDA climbed from $9 million to $36 million. Net profit came in at $17 million, reversing a $26 million loss in the same quarter of 2025. This is the company's fourth consecutive quarter of year-over-year improvement, arriving twelve months after Kodak had disclosed "substantial doubt" about its ability to continue as a going concern.
The part that matters for lab operators sits one level down. Advanced Materials and Chemicals — the segment that houses motion picture film — grew from $75 million to $105 million in revenue, and the "film and chemicals" product line inside it accounted for nearly the entire increase. Kodak does not break out motion picture film as its own reported line, but Vanessa Bendetti, Kodak's Vice President and Head of Motion Picture and Entertainment, has stated that motion picture film revenue grew 36% over the prior two years. A film manufacturer with net cash of $180 million (versus $335 million of net debt a year ago) and falling long-term debt is a very different supplier to plan a two-year production pipeline around than one whose auditors were writing going-concern language.
The Remjet-to-AHU Shift: The Detail That Changes Your Processing Line
The single most consequential technical fact in Kodak's recent disclosures for ECN-2 labs is not a revenue figure — it is a manufacturing change. Kodak is switching its VISION3 stocks from traditional remjet backing to an anti-halation undercoat (AHU) design, across all four VISION3 emulsions and every format from Super 8 through 65mm. Remjet-backed stock requires a dedicated alkaline pre-bath and mechanical scrub step before standard ECN-2 development; AHU stock does not.
That single change is why a one-processor ECN-2 line is now a liability. As VISION3 rolls through its AHU transition, labs will be receiving a growing mix of remjet-bearing legacy stock and AHU/remjet-free stock — often in the same week, sometimes in the same order. Kodak has also stated it will "continue to maximize film volumes by investing in product innovation and expanding capacity," a commitment made directly in its capital allocation principles for what it now calls its highest-growth segment. Rising volume plus a changing stock mix is exactly the combination that exposes a lab running only remjet-capable equipment, or only AHU-capable equipment.
Micrographics Data's ECN-PRO and ECN-PRO3 line is built for precisely this transition:
- ECN-PRO — dedicated remjet pre-bath, scrub, and rinse stages for Kodak VISION3 remjet-bearing stock and other remjet cinema film still in circulation during the changeover.
- ECN-PRO3 — the current-generation remjet-free processor for AHU stock, built for the growing volume of AHU VISION3 and remjet-free formats entering the market as Kodak's transition rolls out.
A lab running both lines is positioned to accept any roll that comes through the door, regardless of which side of Kodak's remjet-to-AHU transition it was manufactured on — without turning away work or improvising a workaround on a converted minilab.
What's Driving the Volume: Demand Signals Beyond the Balance Sheet
Kodak's own pipeline of new film activity backs up the growth numbers. In April 2026, Kodak announced VERITA 200D, an ISO 200 daylight-balanced color negative available in 65mm, 35mm, and 16mm, developed out of production work on Euphoria season 3. Christopher Nolan's The Odyssey, shot entirely on 65mm IMAX film, has crossed $1 billion at the box office — a high-visibility proof point that feature productions are still committing to film at the largest budget tier, not just as a boutique choice. Kodak's own capital allocation language frames Advanced Materials and Chemicals as its "highest-growth segment," with commitments to invest specifically in film capacity.
None of this comes without cost pressure. Kodak has flagged rising silver and aluminum prices working against margin, and issued a price bulletin for its VISION3, EKTACHROME, EASTMAN DOUBLE-X, and TRI-X Reversal motion picture stocks effective January 1, 2026. For labs, that combination — more volume, higher raw stock cost, and a live format transition — is a strong argument for locking in efficient, high-throughput processing now rather than waiting for backlogs to force the decision.
Choosing the Right ECN-2 Processor for a Changing Stock Mix
| Consideration | ECN-PRO | ECN-PRO3 |
|---|---|---|
| Film type | Kodak VISION3 remjet-bearing stock, other remjet cinema stocks | AHU / remjet-free VISION3, Cinestill and other remjet-free ECN-2 stocks |
| Pre-bath step | Dedicated remjet pre-bath, scrub roller, rinse | Not required |
| Best fit | Labs still processing legacy remjet inventory and current remjet cinema releases | Labs scaling for Kodak's AHU rollout and the Cinestill/still-photography ECN-2 crossover market |
| Strategic role in 2026 | Keeps existing remjet-stock clients served through the transition period | Captures growth from AHU-format volume and remjet-free demand |
Running a single processor built for only one chemistry path means either declining remjet work outright or risking contamination and inconsistent results by forcing incompatible film through the wrong line. As Kodak's own transition timeline plays out over the coming format cycles, the labs positioned to serve both remjet and AHU customers without interruption are the ones set up to absorb the volume increase Kodak's Q2 numbers point to.
Frequently Asked Questions
Why did Kodak's film business grow 43% in Q2 2026?
Kodak's "film and chemicals" product line rose from $68 million to $97 million in the quarter, driven largely by motion picture film demand — Kodak's Vice President of Motion Picture and Entertainment has separately stated that motion picture film revenue grew 36% over the prior two years.
What is the difference between remjet and AHU film stock?
Remjet-bearing film uses a carbon-black backing that must be removed in a dedicated alkaline pre-bath before ECN-2 development. AHU (anti-halation undercoat) stock does not carry remjet and skips that pre-bath step entirely. Kodak is transitioning all four VISION3 stocks from remjet to AHU across every format.
Do I need two different ECN-2 processors for remjet and AHU film?
Running mixed remjet and remjet-free stock through the same line without the correct pre-bath configuration risks contamination and inconsistent results. Micrographics Data's ECN-PRO (remjet) and ECN-PRO3 (AHU/remjet-free) are built as a two-product architecture so a lab can process both without compromise.
Is now a good time to invest in ECN-2 processing capacity?
Kodak's growth principles document commits to expanding film capacity, and its Q2 2026 results show four consecutive quarters of year-over-year growth alongside a net cash position. Combined with rising raw material costs already reflected in Kodak's 2026 price bulletin, labs that add capacity ahead of demand are better placed than those reacting to backlogs later.
Get Your Lab Ready for the Next Phase of Film Demand
Kodak's numbers point one direction: more film volume, a live remjet-to-AHU transition, and rising raw stock costs. Micrographics Data supplies the ECN-2 processing line built for exactly that combination — ECN-PRO for remjet-bearing stock, ECN-PRO3 for AHU and remjet-free film.
View the ECN-PRO processor: https://micrographicsdataonline.com/products/ecn2-motion-film-processor-ecn-pro View the ECN-PRO3 processor: https://micrographicsdataonline.com/products/ecn-pro3-professional-ecn2-remjet-free-film-developing-motion-film-processor Contact: sales@micrographicsdata.com | +65 6472 7255
Sources: CineD, "Kodak Posts a Fourth Straight Quarter of Growth – And Film Is Doing the Heavy Lifting," August 14, 2026, https://www.cined.com/kodak-posts-a-fourth-straight-quarter-of-growth-and-film-is-doing-the-heavy-lifting/ · PetaPixel, "Kodak's Transformed Business Has Improved for Four Straight Quarters," August 13, 2026, https://petapixel.com/2026/08/13/kodaks-transformed-business-has-improved-for-four-straight-quarters/